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Abstract
The efficacy of anti-HER2 therapeutics, such as lapatinib and trastuzumab, is limited by primary and acquired resistance.
Cellular adaptations that allow breast cancer cell to survive prolonged HER2 inhibition include de-repression of the
transcription factor FOXO3A with consequent estrogen receptor activation, and/or increased HER3 signaling. Here, we used
low-density arrays, quantitative PCR, and western blotting to determine how HER2 signaling inhibition with lapatinib or PI3K
inhibitors affects the expression of genes involved in breast cancer metastatic spread and overall prognosis. Retroviral
transgenesis was used to express constitutively active forms of Akt in the HER2
+ breast cancer cell line SKBR3, and Grb7 in
MCF7 cells. Specific gene silencing was obtained by siRNAs transfection. A murine BT474 xenograft cancer model was used
to assess the effect of lapatinib on gene expression in vivo. We found that lapatinib induces upregulation of Grb7, an
adaptor protein involved in receptor tyrosine kinase signaling and promoting cell survival and cell migration. Grb7
upregulation induced by lapatinib was found to occur in cancer cells in vitro and in vivo. We demonstrate that Grb7
upregulation is recreated by PI3K inhibitors while being prevented by constitutively active Akt. Thus, Grb7 is repressed by
PI3K signaling and lapatinib-mediated Akt inhibition is responsible for Grb7 de-repression. Finally, we show that Grb7
removal by RNA-interference reduces breast cancer cell viability and increases the activity of lapatinib. In conclusion, Grb7
upregulation is a potentially adverse consequence of HER2 signaling inhibition. Preventing Grb7 accumulation and/or its
interaction with receptor tyrosine kinases may increase the benefit of HER2-targeting drugs.
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Introduction
HER2/ERBB2/neu is amplified in 20–30% breast cancers
where it acts as a driving oncogene conferring propensity to
metastasize and adverse prognosis [1]. HER2 amplification
leads to increased HER2 levels at the cell surface resulting in
aberrant signaling from HER2-containing homo- and hetero-
dimers [2]. HER2 oncogenic properties are thought to result from
increased activation of the signaling cascades downstream of
HER2. Particularly, signaling through the Ras-MAPK cascade is
responsible for cell proliferation, cell migration, and angiogenesis,
while the phosphoinositide 3-kinase (PI3K)-Akt pathway exerts
multiple anti-apoptotic and growth promoting effects [2].
HER2-targeting therapeutics, such as the monoclonal antibody
trastuzumab (Herceptin) and the dual HER2/EGFR tyrosine
kinase inhibitor lapatinib (Tykerb), are successfully applied to the
treatment of patients with HER2
+ breast cancer [3,4,5]. In
addition, recent data indicate that these drugs could potentially
also find applications in cancers of different histology [6,7].
However, the efficacy of anti-HER2 therapeutics is restricted to a
fraction of the patients, and even in those that initially respond to
treatment, acquired resistance is commonly observed [8,9].
Chronic exposure to inhibitors of HER-family proteins results in
cellular adaptations with the potential of reducing the efficacy of
these drugs. Sergina at al. described a feedback mechanism
controlled by Akt whereby Akt inhibition in response to HER2
tyrosine kinase inhibitors leads to HER3 redistribution to the
cell membrane and to sustained HER3 phosphorylation [10].
Increased HER3 signaling would in turn then restore Akt activity
and thus lead to drug resistance. Similarly, prolonged Akt
inhibition in lapatinib-treated cells was shown to de-repress
FOXO3A, a transcription factor that up-regulates estrogen
receptor (ER) signaling [9]. As a result, breast cancer cells that
would previously rely on HER2 signaling for survival, become
supported by ER activity and can thereby escape cell death as a
consequence of HER2 inhibition. Finally, acquired resistance to
trastuzumab in an experimental model was found to correlate with
increased EGFR, EGF, TGF-a, and heregulin levels [11]. Overall,
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inhibition appears to be essential for the design of therapeutic
strategies to overcome resistance and improve clinical outcomes.
Here, we used low-density arrays (LDAs) to assess how HER2
tyrosine kinase inhibition by lapatinib would affect the expression
of a panel of genes involved in breast cancer biology and
metastatic behavior. We show that lapatinib causes rapid
upregulation of Grb7, an adaptor protein that is typically co-
amplified with HER2, participates in HER2 signaling, and
promotes cell survival and cell migration. We identify a negative
feedback loop mediated by Akt as responsible for repressing Grb7.
Finally, we show that preventing Grb7 accumulation by RNA-
interference potentiates the activity of lapatinib.
Materials and Methods
Cells and Reagents
SKBR3, BT474, MCF7, MDA-MB231, and Phoenix cells were
all obtained from ATCC. Cell were grown in RPMI medium
(Sigma-Aldrich Italia, Milan, Italy), supplemented with 10%FBS,
L-glutamine and antibiotics. Lapatinib was generously provided
by GlaxoSmithKline. LY294002, wortmannin, puromycin, G418,
and protamine sulfate, were purchased from Sigma-Aldrich
(Sigma Aldrich Italia, Milan, Italy).
Viability Assays and Cell Cycle Analysis
5610
3 cells/well were seeded in 96 well plates in medium
containing 1% FBS. Cells were allowed to adhere for 24 h and
were subsequently incubated with the indicated drug concentra-
tions. Each condition was tested in triplicate wells. Viability was
assessed 120 h later by Celltiter96 Aqueous1 (Promega Italia,
Milan, Italy) using a standard ELISA reader. Specific death was
calculated with the following formula: 100-[(x-background signal)/
(untreated-background signal)x1.
For cell cycle analysis, adhering cells were resuspended in a
buffer containing 0.1% Na citrate, 0.1% Triton-X, and 50 mg/ml
propodium iodide. Thereafter, the isolated cell nuclei were
analyzed by flow cytometry using a FACS Calibur (Becton
Dickinson, Milan, Italy).
Microscopy
Cells were imaged at room temperature using with the 40X
magnification of a Zeiss AXIOVERT200 microscope, an
Olympus C-4040ZOOM camera, and the software Olympus
CAMEDIA Master 2.5.
Immunostaining
Adhering cells were harvested, washed, and incubated for 159 at
room temperature with a FITC-conjugated anti-TFRC (CD71)
antibody (Becton Dickinson), or a FITC-conjugated anti-EGFR
antibody (sc120-FITC, Santa Cruz Biotechnology, Heidelberg,
Germany). Thereafter, cells were analyzed by flow cytometry on a
FACS Calibur.
Retroviral Transgenesis
The plasmids MSCVpuro-wild type (WT) Akt and MSCVpuro-
Akt S473D [12] were a gift of Dr. Sabatini (Whitehead Institute
for Biomedical Research, Cambridge, MA, USA). pJP1520 and
pJP1520-Grb7 were purchased from the Dana-Farber/Harvard
Cancer Center DNA Resource Core (Boston, MA, USA). 1.5610
6
Phoenix cells were plated in 4 ml medium in 6 cm-dishes and
allowed to adhere for 24 h. Thereafter, cells were transfected with
4 mg plasmid DNA using Transit 293 (Mirus Bio, Madison, WI,
USA) according to the manufacturer’s instructions. The viral
supernatant was harvested 36 and 48 h later and used to infect
SKBR3 or MCF7 cells in 6 cm dishes in the presence of 5 mg/ml
protamine sulfate. Successfully infected cells were selected using
1.5 mg/ml puromycin.
siRNA Transfection
Grb7 siRNAs (ON-TARGET-Plus Smart Pool) and the
respective non targeting control siRNAs were purchased from
Dharmacon (ThermoFisher Scientific Inc., Euroclone, Milan,
Italy). 10
5 cells/well were plated in 12-well plates, allowed to
adhere for 48 h, and then transfected using Dharmafect
(Dharmacon) according to the manufacturer’s instruction. Grb7
silencing was verified by immunoblotting and Q-PCR.
Transient Transfections
2610
5 SKBR3 cells were plated in 6-well plates and allowed to
adhere for 24 h. Thereafter, cell were transfected with 2 mg
plasmid DNA using Lipofectamine (Invitrogen Italia Srl, Milan,
Italy) according to the manufacturer’s instructions. The plasmids
pcDNA3 FOXO1A, pcDNA3 FOXO1A AAA (T24A, S256A,
S319A), pcDNA3 FOXO3A, pcDNA3 FOXO3A AAA (T32A,
S253A, and S315A) were purchased from Addgene (Cambridge,
MA, USA). pcDNA3 was a king gift of Dr. Alberto Inga (National
Cancer Institute, Genoa, Italy). Thereafter, cells were cultured
with 500 mg/ml G418 for two weeks before being used for protein
lysates preparation.
LDAs and Quantitative Real-Time PCR (Q-PCR)
Total RNA was isolated from cell lysates using QIAGEN
RNeasy Mini anion-exchange spin columns (QIAGEN, Hilden,
Germany) according to the manufacturer’s instructions. Total
RNA (1 mg) was reverse-transcribed using SuperScript RTII
(Invitrogen, Karlsruhe, Germany) and oligo(dT) as primers. For
LDAs, a primer collection for a panel of 96 genes selected for their
relevance in breast cancer prognosis and metastatic behaviour
(Table S1) was assembled by Applied Biosystems (Carlsbad, CA,
USA). LDAs and Q-PCRs were performed on a 7900HT Fast
Real Time PCR System (Applied Biosystems). Q-PCRs for GRB7,
GRB2, and RPLP0 were performed with pre-designed primers by
Applied Biosystems. Results were normalized to RPLP0 expres-
sion and plotted as mRNA fold induction in drug-treated versus
vehicle-treated cells using the 2
-DDCT method [13].
Immunoblotting
Cell lysates were prepared by resuspending cells in SDS sample
buffer [6.25 mol/L Tris-HCl (pH 6.8), 2% SDS, 10% glycerol,
2% b-mercaptoethanol, 0.005% bromophenol blue; Boston
Bioproducts, Boston, MA]. Cell lysates were boiled at 100uC for
10 minutes and stored at 220uC for subsequent use. Proteins were
separated on a SDS-polyacrylamide gel and electroblotted to a
polyvinylidene fluoride membrane (Pall Gelman Laboratory, Ann
Arbor, MI). Proteins were visualized by probing the membranes
with the following antibodies: anti-phospho Akt (Ser473), anti-Akt,
anti-HER2 (Cell Signaling Technology, Euroclone, Milan, Italy),
anti-Grb7 (N-20, Santa Cruz Biotechnology), anti-FOXO3a
(rabbit polyclonal, Millipore, Billerica, MA, USA), and c-tubulin
(Sigma Aldrich). Standard enhanced chemiluminescence was used
for protein bands detection.
Co-Immunoprecipitation
Cells (3610
6) were washed twice with ice-cold PBS and
then scraped off the plates in cell-lysis buffer (1% NP40, 20 mM
TRIS/HCl pH 7.4, 0.14 M NaCl, 1mM EDTA, 1mM EGTA)
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cocktail I & II (Sigma-Aldrich). Lysates were prepared after
15 min of incubation on ice by repeated pipetting and centrifu-
gation in a microfuge at 12,000 g for 10 min at 4uC. For
coimmunoprecipitations, a anti-HER2 antibody (Cell Signaling)
was covalently coupled to protein G Dynabeads (2 mgo f
antibodies per 30 ml beads) using BS
3 (Bis[sulfosuccinimidyl]sube-
rate; Pierce, Rockford, IL) according to the manufacturer’s
specification, and then incubated with 1 mg of cell extract
supernatant for 3 h at 4uC. The immunoprecipitates were washed
five times with lysis buffer, eluted with 25 ml of electrophoresis
sample buffer, and heated at 95uC for 5 min. Thereafter, proteins
were separated by immunoblotting, transferred to PVDF mem-
branes and revealed using appropriate antibodies and standard
enhanced chemiluminescence.
Tumor Xenografts in Nude Mice
This study was performed in compliance with the US
Department of Health and Human Services Guide for the Care
and Use of Laboratory Animals and approved by the Internal
Review Board of the Advanced Biotechnology Center (ABC) in
Genoa, Italy. Six- to eight-week-old female BALB/c athymic mice
(nu+/nu+, n=8) were acquired from Charles Rivers Laboratories.
A1 7b-estradiol pellet (Innovative Research of America) was
inserted s.c. to each mouse 1 d before injection with BT474 cells.
2610
7 BT474 cells were injected s.c., and treatment was initiated
when the tumors appeared as established palpable masses (,3
weeks after the injection). 50 mg/kg body weight lapatinib was
given daily for three days by oral gavage in 0.5% hydroxypro-
pylmethycellulose and 0.1% Tween 80. Thereafter, mice were
anesthetized and killed by cervical dislocation. Tumors were
divided in two parts and stored in RNAlater (Ambion-Applied
Biosystems, Milan, Italy) for subsequent RNA extraction, and in
formalin for histological examination (hematoxylin-eosin) and
HER2 immunohistochemistry (HercepTest, Dako, Carpinteria,
CA).
Promoter Analysis
Promoter analysis of the Grb7 gene was performed by
Genomatix software (Genomatix Software Inc., Ann Harbor,
MI, USA).
Statistical Analysis
Each experiment was performed at least three times with similar
results. Unpaired t-tests were performed to evaluate the signifi-
cance of the results.
Results
Gene Expression Modulation in Response to Lapatinib
We were interested in assessing the repercussions of HER2
signaling inhibition on a panel of genes involved in breast cancer
Figure 1. Changes in gene expression in breast cancer cell lines in response to lapatinib. A, B, 1610
6 cells were seeded in 10-cm culture
dishes, allowed to adhere for 24 h and subsequently treated for 12 h with 300 nM lapatinib or vehicle DMSO. Thereafter, cells were harvested,
washed and used for cell cycle analysis (A) or for RNA extraction. Subsequently, LDAs were performed to compare gene expression in lapatinib- vs.
vehicle-treated cells (B). C, 2610
5 SKBR3 cells/well were seeded in 6-well plates, allowed to adhere for 24 h and subsequently treated for 36 h with
300 nM lapatinib or vehicle DMSO. Thereafter, TFRC/CD71 and EGFR expression were determined by flow cytometry. B, results were calculated as
means of four separate experiments. A, C one representative experiment out of four is shown.
doi:10.1371/journal.pone.0009024.g001
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TLDA results is appended as Table S1). To this end, we made use
of HER2-overexpressing (SKBR3 and BT474) and non-HER2-
overexpressing (MCF7 and MDA-MB-231) breast cancer cell
lines. According to previous evidence that lapatinib activity
correlates with the degree of HER2 expression [14], we found
that SKBR3 and BT474 cells underwent G1 cell cycle arrest, and
subsequently died in response to this drug (Figure 1A and data not
shown). Vice versa, in MCF7 and MDA-MB-231 cells lapatinib
showed no effect on cell cycle and viability for concentrations up to
1 mM (Figure 1A and data not shown). SKBR3, BT474, MCF7
and MDA-MB-231 cells were treated with lapatinib (300 nM) and
the gene expression profiles of lapatinib- versus vehicle-treated
cells were determined in low-density arrays. Lapatinib showed a
much greater impact on the gene expression profile of SKBR3 and
BT474 cells as compared to the two non-HER2-overexpressing
cell lines MCF7 and MDA-MB-231 (Figure 1B and Table S1). In
Figure 1B, we arbitrarily chose ,0.5 fold induction and .1.5 fold
induction to define those genes that were down- and up-regulated
by drug treatment, respectively. Applying this criterion, in SKBR3
cells, 6% and 16% of the examined genes were up- and down-
regulated by lapatinib, respectively. In BT474, 10% of the genes
were upregulated while 15% were upregulated. In sharp contrast,
in MCF7 cells only one gene out of eighty two was modulated by
lapatinib (EGF, upregulated), while in MDA-MB-231 no gene up-
or down-regulation was detected according to the previously
defined criterion.
Importantly, several of the observed modifications in gene
expression were known or predictable based on the mode of action
of lapatinib. For instance, CCND1, CCNE1, and CDC25, which
we found to be down-regulated by lapatinib in SKBR3 and BT474
cells, are all involved in the G1/S transition phase of the cell cycle.
Figure 2. Lapatinib and the PI3K inhibitor LY294002 induce Grb7 upregulation. A, 2610
5 SKBR3 or BT474 cells/well were seeded in 6-well
plates, allowed to adhere for 24 h and subsequently treated with 300 nM lapatinib or 20 mM LY294002 for the indicated times. Thereafter, total RNA
was isolated, and Grb7 mRNA levels were compared to those in vehicle-treated cells. B, C, 2610
5 SKBR3 or BT474 cells/well were seeded in 6-well
plates and allowed to adhere for 24 h. Thereafter, cells were treated with 300 nM lapatinib or 20 mM LY294002 for 24 h and then used for protein
lysates preparation (B); or incubated with 300 nM lapatinib for the indicated times before being lysed. Grb7, c-tubulin (B, C), phospho-Akt, and total
Akt (C) levels were determined by immunoblotting. D, 1.5610
3 SKBR3 cells were plated in 10 cm dishes, allowed to adhere, and treated with 300 nM
lapatinib for 36 h. Thereafter, cells were resuspended in lysis buffer and HER2 was immunoprecipitated using a specific anti-HER2 antibody. The
immunoprecipitated protein was separated by SDS PAGE, blotted onto a PVDF membrane and HER2 and Grb7 were detected using appropriate
antibodies. A, Results are presented as means 6 SD of three separate experiments. B-D, One representative experiment out of three is shown.
doi:10.1371/journal.pone.0009024.g002
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cycle arrest observed in response to lapatinib. Moreover, CCND1
downregulation has been documented in primary tumors from
patients treated with this drug [15]. Among the other genes that
were consistently down-regulated by lapatinib in HER2-overex-
pressing cells, GCN5L2 is a still poorly characterized histone
deacetylase whose expression was found to correlate with ERa in
breast cancer [16]. MYBL2 is a transcription factor whose
expression correlates with the risk of relapse in node negative
breast cancer [17]. Moreover, MYBL2 was also found to be
enriched in high-grade ER-negative tumors and to associate with
stem or progenitor function, and with cancer cell proliferation
[18]. Interestingly, in SKBR3 and BT474, lapatinib consistently
down-regulated the transferrin receptor TFRC/CD71 (Figure 1B,
C). Since TFRC expression is promoted by the Akt/mTOR
pathway [19,20], this finding is in line with lapatinib-mediated Akt
inhibition in HER2-overxpressing breast cancer cells [15].
We observed that a fraction of the tested genes was upregulated
by lapatinib in HER2-overexpressing cells. For some of these
changes, it was appealing to speculate that they may result from
feedback loops involving gene de-repression, and be aimed to
compensate for HER2 signaling inhibition. Grb7 and EGFR were
consistently upregulated in SKBR3 and in BT474 cells (Figure 1B,
C). Increased EGFR levels have previously been reported in
response to erlotinib, a small molecule EGFR inhibitor, and to
trastuzumab [11,21]. Using EGFR-specific siRNAs or EGFR-
targeted drugs was proposed as a strategy to counter this
adaptation and induce tumor regression [11,21].
Here, we focused on Grb7 because of its emerging relevance in
breast cancer prognosis, and its supposed role in anticancer drug
Figure 3. Active Akt prevents Grb7 upregulation in response to lapatinib. A-D, SKBR3 cells were transduced with empty MSCV (vector),
MSCVpuro-Akt S473D, or MSCVpuro-WT Akt. A, 2610
5 cells/well were plated in 6-well dishes, allowed to adhere for 24 h and subsequently used for
cell lysates preparation. Phospho-Akt, total Akt and HER2 levels were detected by immunoblotting. B, 5610
3 cells/well were plated in 96-well plates,
allowed to adhere and subsequently treated with lapatinib at the indicated concentrations. Viability was assessed 5 days later by colorimetric assay.
C, D, 2610
5 cells/well were plated in 6-well dishes, allowed to adhere for 24 h and then incubated with or without 300 nM lapatinib (C, D) or 20 mM
LY294002 for 24 h (D). Thereafter, total RNA was isolated and Grb7 (C) and Grb2 (D) mRNA levels were compared to those in vector cells. B-D Results
are shown as means 6 SD of three independent experiments. A, one representative experiment out of three is presented.
doi:10.1371/journal.pone.0009024.g003
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signaling downstream of receptor tyrosine kinases (RTKs)
[24,25,26,27]. Grb7 also plays a role in integrin signaling and in
cell migration through its interaction with focal adhesion kinase
(FAK) [28,29,30,31]. Interestingly, Grb7 is located on the HER2
amplicon, is co-amplified and co-overexpressed with HER2 in
cancer, and physically interacts with HER2, HER3, and HER4
[26,32,33]. Studies in animal models of HER2-driven tumorigen-
esis confirmed that Grb7 and HER2 are usually co-amplified, and
a strong correlation between HER2, phospho-HER2, and Grb7
copy number and protein levels was detected [34,35]. Thus, Grb7
and HER2, at least when amplified and overexpressed, appear act
in concert to drive breast cancer formation.
Grb7 Is Repressed by the PI3K-Akt Pathway
Akt is involved in several forms of adaptations and feedback
loops responsible for modulating RTK signaling [9,10]. We
therefore hypothesized that Grb7 upregulation as a consequence
of HER2 and EGFR tyrosine kinase inhibition would reflect
inactivation of the PI3K-Akt signal transduction cascade. In line
with this hypothesis, we found that lapatinib and the PI3K inhibitor
LY296004 both caused rapid upregulation of Grb7 mRNA in
SKBR3 and BT474 cells (Figure 2A). Changes in Grb7 mRNA
translated into a striking increase in Grb7 protein levels in response
to lapatinib, LY294002, and wortmannin, another PI3K inhibitor
(Figure 2B and data not shown). Figure 2C shows a time course
experiment where Grb7 protein and Akt phosphorylation (Ser473)
are monitored over time in response to lapatinib. Grb7 upregula-
tion appears to be a relatively early event, being well detectable
already after a 12 h treatment. Interestingly, in co-immunoprecip-
itation experiments, we found that Grb7-HER2 physical interac-
tion is maintained also in lapatinib treated cells (Figure 2D).
To confirm the involvement of Akt inhibition in Grb7
upregulation via lapatinib, we engineered SKBR3 cells to express
a constitutively active Akt isoform (Akt S473D) or overexpress a
WT Akt allele [12]. While WT Akt overexpression led to increased
phospho-Akt levels (Ser473), this effect was not detected with the
mutant isoform, possibly due to conformational changes in the
antibody-binding site as a consequence of the mutation itself
(Figure 3A). Nonetheless, both alleles increased cell size in MCF7
cells (data not shown) and reduced susceptibility to lapatinib
in SKBR3 cells (Figure 3B). Expression of either Akt S473D
or WT Akt prevented Grb7 upregulation in response to lap-
atinib, confirming that active Akt represses Grb7 transcription
(Figure 3C). Finally, we investigated whether this type of
regulatory mechanism would apply to Grb2, another adaptor
protein implicated in RTK signaling [36]. In this case, no Grb2
modulation in response to the pharmacological treatments was
observed, nor did constitutively active Akt have any effect on Grb2
mRNA levels (Figure 3D). Thus, PI3K-mediated control does not
appear to indiscriminately act on all HER interaction partners.
Akt is responsible for inhibiting the forkhead box-O (FOXO)
transcription factors by phosphorylating them on several residues
and thereby inducing their sequestration in the cytoplasm by 14-3-
3 proteins [9]. FOXO3A re-activation as a consequence of Akt
inhibition by lapatinib was shown to be responsible for increased
ER transcription and, thereby, for acquired resistance to lapatinib
itself [9]. Thus, we speculated that FOXO transcription factors
could also be involved in the increased Grb7 transcription
observed in response to lapatinib. Indeed, we detected several
putative FOXO consensus binding sites in the Grb7 promoter
(102–118, 207–223, 307–323, 336–352, 338–354, 487–503). To
evaluate a potential role of FOXO3A in Grb7 expression, we
engineered SKBR3 cells to overexpress a wild type FOXO3A
Figure 4. Lapatinib induces Grb7 upregulation in BT474 cells in vivo. A, B, BT474 tumor xenograft-bearing mice were given 50 mg/kg body
weight lapatinib (n=4) or vehicle DMSO (n=4) daily for three days. At day 4, mice were euthanized and tumors were extracted and used for
histology/immunohistochemistry and for RNA isolation. B, BT474 xenograft histology (H&E) and HER2 expression as detected in a vehicle-treated
mouse. C, Grb7 mRNA level in the tumors was determined by Q-PCR in lapatinib vs. vehicle-treated mice.
doi:10.1371/journal.pone.0009024.g004
Grb7 Levels Regulated by HER2
PLoS ONE | www.plosone.org 6 February 2010 | Volume 5 | Issue 2 | e9024allele or a FOXO3A isoform in which all the relevant
phosphorylation sites are mutated rendering it constitutively active
(FOXO3A AAA) [37]. However, neither of these modifications
resulted in increased Grb7 expression (Figure S1). Similar results
were obtained by overexpressing FOXO1A and its constitutively
active isoform (FOXO1A AAA) (data not shown) [38]. Therefore,
Grb7 upregulation in response to Akt inhibition appears to be
independent of FOXO3A or FOXO1A.
Grb7 Upregulation in Cancer Cells via Lapatinib Occurs In
Vivo
To assess whether Grb7 upregulation due to lapatinib would
occur in cancer cells in vivo, we made use of a BT474 murine
xenograft model (Figure 4A). Figure 4B shows the typical
histological appearance of these tumors as well as the strong
HER2 overexpression detected by immunohistochemistry. Mice
with established BT474 tumor masses were treated with lapatinib
(or vehicle) for three days. Thereafter, Grb7 mRNA in the tumors
was quantified by Q-PCR. Indeed, lapatinib treatment upregu-
lated Grb7 mRNA by about two folds, indicating that increased
Grb7 levels are likely to be found in HER2
+ tumors in vivo in
response to this drug.
Grb7 Silencing Increases the Efficacy of Lapatinib
Grb7 promotes cell survival and increases cell proliferation
[24,39,40]. Therefore, we sought to determine whether preventing
Grb7 accumulation in response to lapatinib would improve the
efficacy of this drug. To this aim, we silenced Grb7 using a pool of
Figure 5. Grb7 silencing reduces cell viability and increases lapatinib efficacy. A-E, SKBR3 or BT474 cells were transfected with Grb7 siRNA
or non-targeting control siRNA (CNTR siRNA). A, 2610
5 SKBR3 cells/well were seeded in 6-well plates, allowed to adhere for 48 h and subsequently
used for protein lysates preparation. Grb7, phospho-Akt, total Akt and c-tubulin levels were determined by immunoblotting. B, BT474 cells were
transfected with Grb7 siRNA or CNTR siRNA and imaged by light microscopy five days later. C, D, 5610
3 siRNA-transfected or untransfected SKBR3/
well were seeded in 96-well plates, allowed to adhere for 24 h and subsequently treated with or without lapatinib at the indicated concentrations.
Five days later, viability was determined and compared to that of untransfected SKBR3 (C); lapatinib-specific death was determined by normalizing to
baseline cell death of CNTR siRNAs- or Grb7 siRNAs-transfected SKBR3 (D). E, SKBR3 cells were transfected with Grb7 siRNA or CNTR siRNA. mRNA was
extracted 3 days after transfection and gene expression was detected by LDAs. A, B, One representative experiment out of three is shown. C, D,
Results are means 6 SD of four independent experiments. E, Results were calculated as means of two separate experiments. *: p,0.05.
doi:10.1371/journal.pone.0009024.g005
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(Figure 5A). At the biochemical level, SKBR3 cells with silenced
Grb7 showed reduced Akt phosphorylation, consistent with the
notion that Grb7 participates in signal transduction downstream of
HER2 [24]. In line with a recent report, Grb7 removal reduced
cell viability in SKBR3 and BT474 cells. On the contrary, MCF7,
that do not have HER2 and Grb7 amplification, and express very
low Grb7 levels, were unaffected (Figure 5B, C, and data not
shown) [41]. Finally, SKBR3 cells with silenced Grb7 expression
were more susceptible to lapatinib for concentrations up to
300 nM (Figure 5D). Upon lapatinib concentrations .300 nM,
the difference between SKBR3 cells with silenced Grb7 and
control cells was no longer significant, possibly due to the
pronounced cytotoxic activity of lapatinib alone.
To gain insight into the mechanism whereby Grb7 inhibition/
silencing affects cell viability and sensitizes cells to lapatinib, we
performed cell cycle analysis and low-density arrays in SKBR3
cells with silenced Grb7. Reduced Grb7 levels did not have a
major impact on the cell cycle profile (data not shown). On the
other hand, similar to what observed with lapatinib, Grb7
removal decreased TFRC/CD71 expression, in line with a role
for Grb7 in the HER2-Akt-mTOR pathway (Figure 5E). Finally,
we overexpressed Grb7 in MCF7 cells, which normally express
low levels of this protein (Figure 6A). Here, Grb7 expression
would typically result in an increase in cell size (Figure 6B),
which again is consistent with a role for this adaptor protein in
pathways controlling cell growth and cell size such as the Akt-
mTOR axis.
Discussion
In this study, we identify a functional interplay between HER2
and its interactor Grb7 whereby HER2 signaling represses Grb7
using the PI3K-Akt arm of its downstream signaling cascades.
Inhibition of HER2 tyrosine kinase activity or of PI3K/Akt de-
represses Grb7 causing its rapid upregulation (Figure 7). Notice-
ably, increased Grb7 expression appears to be independent of
FOXO3A and FOXO1A re-activation in lapatinib-treated cells
[9].
Our study reinforces the concept that adaptations involving
gene de-repression and/or protein relocalization/posttranslational
modification (as in the case of HER3) occur as a consequence of
RTK inhibition and have the potential to reduce the benefit of
RTK-targeting therapeutics [9,10].
Grb7 acts as a pro-survival factor in breast cancer cells as shown
by the fact that RNAi-mediated removal of this protein reduces
cell viability. The mechanisms whereby Grb7 promotes cell
survival are still unclear. Our data indicate a role for Grb7 in the
HER2-Akt-mTOR pathway. Grb7 silencing reduces Akt activa-
tion and leads to TFRC/CD71 downregulation [19,20]. More-
over, Grb7 overexpression in MCF7 cells increases their cell size.
On the other hand, Grb7 may also owe its activity as a pro-
survival factor to its interaction with other RTK or with other
intracellular proteins [25,27]. Finally, due to its participation in
integrin signaling via FAK, Grb7 promotes cell migration
[28,29,30,31].
In line with its biological properties, Grb7 belongs to a group of
genes conferring adverse prognosis in node-negative breast cancer
[17]. In addition, Grb7 upregulation was shown to confer
resistance to hormone therapy in breast cancer [22]. Acquired
resistance to lapatinib and trastuzumab frequently occurs, possibly
as a consequence of FOXO3A de-repression and increased ER
signaling [8,9]. It is conceivable that, in these conditions, Grb7
accumulation as a consequence of HER2 signaling inhibition may
increase breast cancer cell aggressiveness and thereby speed up
metastatic disease progression.
Our observation that Grb7 silencing increases lapatinib activity
provides the proof of principle that interfering with this adaptor
protein may be beneficial, although the mechanism(s) underlying
this synergism is (are) not entirely clear. Grb7 upregulation per se
Figure 6. Grb7 overexpression increases cell size in MCF7 cells. MCF7 cells were transduced with Grb7 or with the respective empty vector
(vec). A, 2610
5 cells/well were plated in 6-well plates, allowed to adhere and then used for cell lysate preparation. Grb7 and c-tubulin levels were
determined by immunoblotting. B, 10
6 MCF7 cells engineered to express Grb7 or the respective vector control cells were cultured in 10-cm dishes
and allowed to reach a 40–60% confluence. Subsequently, cells were harvested, washed and analyzed by flow cytometry. Histograms represent the
cell forward scatter (FSC).
doi:10.1371/journal.pone.0009024.g006
Figure 7. A feedback loop mediated by the PI3K-Akt axis
controls Grb7 expression. Grb7 interacts with HER2, participates in
HER2 signaling, and promotes cell survival and cell migration. HER2
exerts a repressive control on Grb7 via the PI3K-Akt pathway. Inhibition
of HER2 signaling (e.g. by lapatinib) de-represses Grb7 causing its rapid
upregulation. Reducing Grb7 with RNAi or preventing its interaction
with HER2 using protein-protein interaction inhibitors may help
increase the efficacy of anti-HER2 therapeutics and avoid the adverse
consequences of Grb7 oncogenic activity.
doi:10.1371/journal.pone.0009024.g007
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Erk phosphorylation, data not shown) in the presence of lapatinib
(at least in the incubation times tested in our experiments)
regardless of a persistent interaction with HER2. Thus, Grb7
silencing is unlikely to cooperate with lapatinib by eliminating a
residual Akt activity. Vice versa, it appears likelier that Grb7
reduction (also) affect other signaling pathways/intracellular
processes whose obstruction increase susceptibility to HER2
inhibition.
RNAi-based therapeutics are eventually being developed and
Grb7 siRNAs may thus potentially be coupled to anti-HER2 drugs
[42]. Moreover, peptide inhibitors of Grb7-HER2 interaction are
available and were previously shown to reduce proliferation and
migration in various cancer cell lines [37,43]. Combining these
peptides with HER2-inhibiting drugs may help circumvent the
negative effects of increased Grb7 levels.
In conclusion, Grb7 upregulation is a potentially adverse
molecular side effect of HER2 signaling inhibition. Interfering
with Grb7 accumulation may be advisable given its oncogenic
activity and its capacity to increase the metastatic potential of a
cell.
Supporting Information
Table S1 Gene expression modulation by lapatinib in breast
cancer cell lines. Supporting material. Gene list and LDA results.
Found at: doi:10.1371/journal.pone.0009024.s001 (0.16 MB
DOC)
Figure S1 FOXO3A does not affect Grb7 expression in SKBR3
cells. SKBR3 cells were transfected with plasmids encoding WT
FOXO3A, FOXO3A AAA or the empty vector (pcDNA3) as a
control. Cells were selected for 2 weeks using G418 before being
used for cell lysates preparation. FOXO3A, Grb7, and c-tubulin
expression were detected by immunoblotting.
Found at: doi:10.1371/journal.pone.0009024.s002 (0.70 MB TIF)
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